Biliverdin Reductase B Is a Plasma Biomarker for Intraplaque Hemorrhage and a Predictor of Ischemic Stroke in Patients with Symptomatic Carotid Atherosclerosis

Author:

Chemaly Melody1ORCID,Marlevi David12,Iglesias Maria-Jesus3ORCID,Lengquist Mariette1,Kronqvist Malin1,Bos Daniel45,van Dam-Nolen Dianne H. K.4ORCID,van der Kolk Anja67,Hendrikse Jeroen7,Kassem Mohamed8ORCID,Matic Ljubica1,Odeberg Jacob3910,de Vries Margreet R.11ORCID,Kooi M. Eline8ORCID,Hedin Ulf112

Affiliation:

1. Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden

2. Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02142, USA

3. Science for Life Laboratory, Department of Protein Science, School of Engineering Sciences in Chemistry/Biotechnology and Health, KTH Royal Institute of Technology, 11428 Stockholm, Sweden

4. Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands

5. Department of Epidemiology, Erasmus MC, University Medical Center, 3000 CA Rotterdam, The Netherlands

6. Department of Medical Imaging, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands

7. Department of Radiology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands

8. Department of Radiology and Nuclear Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands

9. Department of Hematology, Karolinska University Hospital, Huddinge, 14152 Stockholm, Sweden

10. Department of Clinical Medicine, UiT—The Arctic University of Norway, 9019 Tromsø, Norway

11. Einthoven Laboratory, Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

12. Department of Vascular Surgery, Karolinska University Hospital, 17176 Stockholm, Sweden

Abstract

Background: Intraplaque hemorrhage (IPH) is a hallmark of atherosclerotic plaque instability. Biliverdin reductase B (BLVRB) is enriched in plasma and plaques from patients with symptomatic carotid atherosclerosis and functionally associated with IPH. Objective: We explored the biomarker potential of plasma BLVRB through (1) its correlation with IPH in carotid plaques assessed by magnetic resonance imaging (MRI), and with recurrent ischemic stroke, and (2) its use for monitoring pharmacotherapy targeting IPH in a preclinical setting. Methods: Plasma BLVRB levels were measured in patients with symptomatic carotid atherosclerosis from the PARISK study (n = 177, 5 year follow-up) with and without IPH as indicated by MRI. Plasma BLVRB levels were also measured in a mouse vein graft model of IPH at baseline and following antiangiogenic therapy targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Results: Plasma BLVRB levels were significantly higher in patients with IPH (737.32 ± 693.21 vs. 520.94 ± 499.43 mean fluorescent intensity (MFI), p = 0.033), but had no association with baseline clinical and biological parameters. Plasma BLVRB levels were also significantly higher in patients who developed recurrent ischemic stroke (1099.34 ± 928.49 vs. 582.07 ± 545.34 MFI, HR = 1.600, CI [1.092–2.344]; p = 0.016). Plasma BLVRB levels were significantly reduced following prevention of IPH by anti-VEGFR-2 therapy in mouse vein grafts (1189 ± 258.73 vs. 1752 ± 366.84 MFI; p = 0.004). Conclusions: Plasma BLVRB was associated with IPH and increased risk of recurrent ischemic stroke in patients with symptomatic low- to moderate-grade carotid stenosis, indicating the capacity to monitor the efficacy of IPH-preventive pharmacotherapy in an animal model. Together, these results suggest the utility of plasma BLVRB as a biomarker for atherosclerotic plaque instability.

Funder

Stockholm County

Swedish Heart–Lung Foundation

Swedish Research Council

HelseNord

Karolinska Institutet

King Gustav Vth and Queen Victorias Foundation

Center for Translational Molecular Medicine

PARISK

Netherlands Heart Foundation

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Publisher

MDPI AG

Subject

Molecular Biology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3